In a clinical trial, an extended median survival of 19 months has also been reported for diabetic patients with glioblastoma who received additional treatment with PPARγ agonists, compared to 6 months of extended survival for patients receiving the standard treatment (115). Here, PPARG is linked to glioblastoma.